Skip to Main content Skip to Navigation
New interface
Journal articles

Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection

Abstract : The COVID-19 pandemic has spread worldwide, yet the role of antiviral T cell immunity during infection and the contribution of immune checkpoints remain unclear. By prospectively following a cohort of 292 patients with melanoma, half of which treated with immune checkpoint inhibitors (ICIs), we identified 15 patients with acute or convalescent COVID-19 and investigated their transcriptomic, proteomic, and cellular profiles. We found that ICI treatment was not associated with severe COVID-19 and did not alter the induction of inflammatory and type I interferon responses. In-depth phenotyping demonstrated expansion of CD8 effector memory T cells, enhanced T cell activation, and impaired plasmablast induction in ICI-treated COVID-19 patients. The evaluation of specific adaptive immunity in convalescent patients showed higher spike (S), nucleoprotein (N), and membrane (M) antigen-specific T cell responses and similar induction of spike-specific antibody responses. Our findings provide evidence that ICI during COVID-19 enhanced T cell immunity without exacerbating inflammation.
Document type :
Journal articles
Complete list of metadata
Contributor : Marie-Christine Vougny Connect in order to contact the contributor
Submitted on : Friday, September 3, 2021 - 2:26:50 PM
Last modification on : Thursday, September 1, 2022 - 3:54:29 AM
Long-term archiving on: : Saturday, December 4, 2021 - 7:19:42 PM


Publication funded by an institution


Distributed under a Creative Commons Attribution 4.0 International License



Nader Yatim, Jeremy Boussier, Pauline Tetu, Nikaïa Smith, Timothée Bruel, et al.. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. Science Advances , 2021, 7 (34), pp.eabg4081. ⟨10.1126/sciadv.abg4081⟩. ⟨pasteur-03334080⟩



Record views


Files downloads